Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 6, 1998, Pages 811-815

  Suling, W J ^a   Reynolds, R C ^a   Barrow, E W ^a   Wilson, L N ^a   Piper, J R ^a   Barrow, W W ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE INHIBITOR; PTERIDINE DERIVATIVE; TRIMETHOPRIM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANIMALS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; FOLIC ACID ANTAGONISTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; MYCOBACTERIUM TUBERCULOSIS; PTERIDINES; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM; TUBERCULOSIS; VERO CELLS;

EID: 0032444693     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.6.811     Document Type: Article

References (10)

1. Ellner, J. J., Goldberger, M. J. & Parenti, D. M. (1991). Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. Journal of Infectious Diseases 163, 1326-35.
2. Snider, D. E. & La Montagne, J. R. (1994). The neglected global tuberculosis problem: a report of the 1992 World Congress on Tuberculosis. Journal of Infectious Diseases 169, 1189-96.
3. Hitchings, G. H. (1989). Nobel lecture in physiology or medicine - 1988. Selective inhibitors of dihydrofolate reductase. In Vitro Cellular and Developmental Biology 25, 303-10.
4. Czaplinski, K.-H., Hänsel, W., Wiese, M. & Seydel, J. K. (1995). New benzylpyrimidines: inhibition of DHFR from various species. QSAR, CoMFA and PC analysis. European Journal of Medicinal Chemistry 30, 779-87.
5. Piper, J. R., Johnson, C. A., Krauth, C. A., Carter, R. L., Hosmer, C. A., Queener, S. F. et al. (1996). Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations. Journal of Medicinal Chemistry 39, 1271-80.
6. Wright, E. L., Quenelle, D. C., Suling, W. J. & Barrow, W. W. (1996). Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies. Antimicrobial Agents and Chemotherapy 40, 2206-8.
7. Yajko, D. M., Madej, J. J., Lancaster, M. V., Sanders, C. A., Cawthon, V. L., Gee, B. et al. (1995). Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. Journal of Clinical Microbiology 33, 2324-7.
8. Collins, L. & Franzblau, S. G. (1997). Microplate alamar blue assay versus BACTEC 460 System for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrobial Agents and Chemotherapy 41, 1004-9.
9. Zywno-van Ginkel, S., Dooley, T. P., Suling, W. J. & Barrow, W. W. (1997). Identification and cloning of the Mycobacterium avium folA gene, required for dihydrofolate reductase activity. FEMS Microbiology Letters 156, 69-78.
10. Colwell, W. T., Brown, W. H., DeGraw, J. I. & Morrison, N. E. (1979). Inhibition of mycobacterial dihydrofolic reductase by 2,4-diamino-6-alkylpteridines and deazapteridines. In Chemistry and Biology of Pteridines (Kisliuk, R. L. & Brown, G. M., Eds), pp. 215-8. Elsevier North Holland, Inc., Amsterdam.